Indefinite Delivery Contract SPE2DB25D9756

This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The single-award IDC, valued at up to $499,999,999, covers the provision of a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide under the SPE2DB program.

The contract includes the delivery of a wide variety of pharmaceutical items, from common medications such as antibiotics, pain relievers, and cardiovascular drugs, to specialized products like flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications. These products are primarily distributed to the DLA's Medical Supply Chain division, which then delivers them to various Department of Defense (DoD) healthcare facilities globally. The IDC, which runs through November 30, 2026, complements DMS Pharmaceutical Group's existing prime vendor contracts for the direct distribution of prescription drugs and pharmacy services to DoD sites, solidifying the company's role as a critical supplier in the federal pharmaceutical supply chain.